本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Spruce Biosciences, Inc.

53.70
-0.6500-1.20%
成交量:8.85萬
成交額:486.46萬
市值:1.54億
市盈率:-1.40
高:56.08
開:54.78
低:53.09
收:54.35
52周最高:240.00
52周最低:7.26
股本:287.40萬
流通股本:228.65萬
量比:0.70
換手率:3.87%
股息:- -
股息率:- -
每股收益(TTM):-38.4300
每股收益(LYR):-50.8298
淨資產收益率:-105.98%
總資產收益率:-40.03%
市淨率:1.84
市盈率(LYR):-1.06

資料載入中...

2024/05/24

重要事件披露

Form 8-K - Current report
2024/05/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/13

重要事件披露

Form 8-K - Current report
2024/04/30

重要事件披露

Form 8-K - Current report
2024/04/25

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/03/28

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/28

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/03/25

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/18

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/03/18

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/18

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/03/13

重要事件披露

Form 8-K - Current report
2024/03/07

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/15

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/06

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]